Market Research Logo

Glioblastoma Multiforme (GBM) - Pipeline Review, H1 2018

Glioblastoma Multiforme (GBM) - Pipeline Review, H1 2018

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Glioblastoma Multiforme (GBM) - Pipeline Review, H1 2018, provides an overview of the Glioblastoma Multiforme (GBM) (Oncology) pipeline landscape.

Glioblastoma also known as glioblastoma multiforme is a fast-growing glioma that develops from star-shaped glial cells that support the health of the nerve cells within the brain. Symptoms include headaches, blurred vision, nausea, vomiting, memory loss, speech difficulty, muscle weakness and loss of appetite. Risk factors include gender (male) and age. Treatment includes surgery, radiation therapy and chemotherapy.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Glioblastoma Multiforme (GBM) - Pipeline Review, H1 2018, provides comprehensive information on the therapeutics under development for Glioblastoma Multiforme (GBM) (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Glioblastoma Multiforme (GBM) (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Glioblastoma Multiforme (GBM) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, Phase 0, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 10, 108, 67, 1, 9, 160, 28 and 6 respectively. Similarly, the Universities portfolio in Phase III, Phase II, Phase I, Phase 0, Preclinical and Discovery stages comprises 1, 11, 15, 1, 43 and 10 molecules, respectively.

Glioblastoma Multiforme (GBM) (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Glioblastoma Multiforme (GBM) (Oncology).
  • The pipeline guide reviews pipeline therapeutics for Glioblastoma Multiforme (GBM) (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Glioblastoma Multiforme (GBM) (Oncology) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Glioblastoma Multiforme (GBM) (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Glioblastoma Multiforme (GBM) (Oncology)
Reasons to buy
  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Glioblastoma Multiforme (GBM) (Oncology).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Glioblastoma Multiforme (GBM) (Oncology) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.


Introduction
Glioblastoma Multiforme (GBM) - Overview
Glioblastoma Multiforme (GBM) - Therapeutics Development
Glioblastoma Multiforme (GBM) - Therapeutics Assessment
Glioblastoma Multiforme (GBM) - Companies Involved in Therapeutics Development
Glioblastoma Multiforme (GBM) - Drug Profiles
Glioblastoma Multiforme (GBM) - Dormant Projects
Glioblastoma Multiforme (GBM) - Discontinued Products
Glioblastoma Multiforme (GBM) - Product Development Milestones
Appendix 1713
List of Tables
Number of Products under Development for Glioblastoma Multiforme (GBM), H1 2018
Number of Products under Development by Companies, H1 2018
Number of Products under Development by Companies, H1 2018 (Contd..1), H1 2018
Number of Products under Development by Companies, H1 2018 (Contd..2), H1 2018
Number of Products under Development by Companies, H1 2018 (Contd..3), H1 2018
Number of Products under Development by Companies, H1 2018 (Contd..4), H1 2018
Number of Products under Development by Companies, H1 2018 (Contd..5), H1 2018
Number of Products under Development by Companies, H1 2018 (Contd..6), H1 2018
Number of Products under Development by Companies, H1 2018 (Contd..7), H1 2018
Number of Products under Development by Companies, H1 2018 (Contd..8), H1 2018
Number of Products under Development by Companies, H1 2018 (Contd..9), H1 2018
Number of Products under Development by Companies, H1 2018 (Contd..10), H1 2018
Number of Products under Development by Companies, H1 2018 (Contd..11), H1 2018
Number of Products under Development by Companies, H1 2018 (Contd..12), H1 2018
Number of Products under Development by Companies, H1 2018 (Contd..13), H1 2018
Number of Products under Development by Companies, H1 2018 (Contd..14), H1 2018
Number of Products under Development by Universities/Institutes, H1 2018
Number of Products under Development by Universities/Institutes, H1 2018 (Contd..1), H1 2018
Number of Products under Development by Universities/Institutes, H1 2018 (Contd..2), H1 2018
Products under Development by Companies, H1 2018
Products under Development by Companies, H1 2018 (Contd..1), H1 2018
Products under Development by Companies, H1 2018 (Contd..2), H1 2018
Products under Development by Companies, H1 2018 (Contd..3), H1 2018
Products under Development by Companies, H1 2018 (Contd..4), H1 2018
Products under Development by Companies, H1 2018 (Contd..5), H1 2018
Products under Development by Companies, H1 2018 (Contd..6), H1 2018
Products under Development by Companies, H1 2018 (Contd..7), H1 2018
Products under Development by Companies, H1 2018 (Contd..8), H1 2018
Products under Development by Companies, H1 2018 (Contd..9), H1 2018
Products under Development by Companies, H1 2018 (Contd..10), H1 2018
Products under Development by Companies, H1 2018 (Contd..11), H1 2018
Products under Development by Companies, H1 2018 (Contd..12), H1 2018
Products under Development by Companies, H1 2018 (Contd..13), H1 2018
Products under Development by Companies, H1 2018 (Contd..14), H1 2018
Products under Development by Companies, H1 2018 (Contd..15), H1 2018
Products under Development by Companies, H1 2018 (Contd..16), H1 2018
Products under Development by Companies, H1 2018 (Contd..17), H1 2018
Products under Development by Companies, H1 2018 (Contd..18), H1 2018
Products under Development by Companies, H1 2018 (Contd..19), H1 2018
Products under Development by Companies, H1 2018 (Contd..20), H1 2018
Products under Development by Companies, H1 2018 (Contd..21), H1 2018
Products under Development by Universities/Institutes, H1 2018
Products under Development by Universities/Institutes, H1 2018 (Contd..1), H1 2018
Products under Development by Universities/Institutes, H1 2018 (Contd..2), H1 2018
Products under Development by Universities/Institutes, H1 2018 (Contd..3), H1 2018
Products under Development by Universities/Institutes, H1 2018 (Contd..4), H1 2018
Number of Products by Stage and Target, H1 2018
Number of Products by Stage and Target, H1 2018 (Contd..1), H1 2018
Number of Products by Stage and Target, H1 2018 (Contd..2), H1 2018
Number of Products by Stage and Target, H1 2018 (Contd..3), H1 2018
Number of Products by Stage and Target, H1 2018 (Contd..4), H1 2018
Number of Products by Stage and Target, H1 2018 (Contd..5), H1 2018
Number of Products by Stage and Target, H1 2018 (Contd..6), H1 2018
Number of Products by Stage and Target, H1 2018 (Contd..7), H1 2018
Number of Products by Stage and Target, H1 2018 (Contd..8), H1 2018
Number of Products by Stage and Target, H1 2018 (Contd..9), H1 2018
Number of Products by Stage and Mechanism of Action, H1 2018
Number of Products by Stage and Mechanism of Action, H1 2018 (Contd..1), H1 2018
Number of Products by Stage and Mechanism of Action, H1 2018 (Contd..2), H1 2018
Number of Products by Stage and Mechanism of Action, H1 2018 (Contd..3), H1 2018
Number of Products by Stage and Mechanism of Action, H1 2018 (Contd..4), H1 2018
Number of Products by Stage and Mechanism of Action, H1 2018 (Contd..5), H1 2018
Number of Products by Stage and Mechanism of Action, H1 2018 (Contd..6), H1 2018
Number of Products by Stage and Mechanism of Action, H1 2018 (Contd..7), H1 2018
Number of Products by Stage and Mechanism of Action, H1 2018 (Contd..8), H1 2018
Number of Products by Stage and Mechanism of Action, H1 2018 (Contd..9), H1 2018
Number of Products by Stage and Route of Administration, H1 2018
Number of Products by Stage and Molecule Type, H1 2018
Glioblastoma Multiforme (GBM) - Pipeline by AbbVie Inc, H1 2018
Glioblastoma Multiforme (GBM) - Pipeline by Actuate Therapeutics Inc, H1 2018
Glioblastoma Multiforme (GBM) - Pipeline by Aduro BioTech Inc, H1 2018
Glioblastoma Multiforme (GBM) - Pipeline by Advantagene Inc, H1 2018
Glioblastoma Multiforme (GBM) - Pipeline by Advenchen Laboratories LLC, H1 2018
Glioblastoma Multiforme (GBM) - Pipeline by Agenus Inc, H1 2018
List of Figures
Number of Products under Development for Glioblastoma Multiforme (GBM), H1 2018
Number of Products under Development by Companies, H1 2018
Number of Products under Development by Universities/Institutes, H1 2018
Number of Products by Top 10 Targets, H1 2018
Number of Products by Stage and Top 10 Targets, H1 2018
Number of Products by Top 10 Mechanism of Actions, H1 2018
Number of Products by Stage and Top 10 Mechanism of Actions, H1 2018
Number of Products by Top 10 Routes of Administration, H1 2018
Number of Products by Stage and Top 10 Routes of Administration, H1 2018
Number of Products by Top 10 Molecule Types, H1 2018
Number of Products by Stage and Top 10 Molecule Types, H1 2018

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report